Opendata, web and dolomites

ECRC SIGNED

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ECRC project word cloud

Explore the words cloud of the ECRC project. It provides you a very rough idea of what is the project "ECRC" about.

blueprint    2019    award    nature    timing    vaccines    urgency    rvfv    context    criteria    incentives    strengthen    entities    justified    licensure    pathogens    2018    income    accelerate    eligibility    remaining    ebola    launched    regulations    align    rvf    diseases    action    ec    priorities    deemed    chikv    vaccine    proposals    benefit    clinical    virus    outbreak    relates    identification    inherently    sga    humans    rift    mechanism    generating    january    encouraged    pipeline    few    validation    standard    emergencies    launch    correlates    cepi    ll    aligned    evd    market    rapid    candidates    cfp3    advantage    co    protective    duly    list    outbreaks    afforded    cfp3i    public    progression    valley    chikungunya    mitigate    risk    efforts    launching    health    quite    cfp    middle    scope    fda    approval    countries    unpredictable    sub    risks    calls    structured    regulatory    fever    interim    cfp3ii    feasible    agree    promise    understand    investments    grant    lot    ema    stage    chik    gaps    mid    leverage    lacking    despite    stated    protection    mature    meet    efficacy   

Project "ECRC" data sheet

The following table provides information about the project.

Coordinator
COALITION FOR EPIDEMIC PREPAREDNESS INNOVATION 

Organization address
address: MARCUS THRANSES GATE 2
city: OSLO
postcode: 473
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Total cost 51˙428˙572 €
 EC max contribution 36˙000˙000 € (70%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SGA-SC1-CEPI-2019
 Funding Scheme SGA-CSA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    COALITION FOR EPIDEMIC PREPAREDNESS INNOVATION NO (OSLO) coordinator 36˙000˙000.00

Map

 Project objective

The objective of this specific grant agreement (SGA) is to leverage co-funding from the European Commission to accelerate the development of vaccines against Rift Valley Fever (RVF), Chikungunya (CHIK) and Ebola virus diseases (EVD).

• RVF and CHIK vaccine development will be addressed by CEPI’s third Call for Proposals (CFP3), and it will structured through launching two sub-calls; CFP3i and CFP3ii. This SGA only relates to CFP3i, and has the following objectives: a) For RVFV vaccines, to support clinical testing or activities enabling clinical Phase l/ll testing of the most advanced RVFV candidates, including identification of correlates of protection and their validation, which can facilitate future regulatory approval. b) For CHIKV vaccines, to support the rapid progression of the most advanced clinical CHIKV vaccine candidates through mid-stage and late-stage clinical development, and to support activities enabling future efficacy testing, including identification of correlates of protection and their validation that can facilitate future regulatory approval. The call will be launched January 2019 and will be open to all entities that meet the eligibility criteria and agree to CEPI’s award conditions – which are aligned with EU regulations.

EVD vaccine development will focus on addressing the remaining evidence gaps towards the licensure by FDA and/or EMA of the leading vaccine candidates, particularly on generating evidence of the protective efficacy of the vaccines in humans in the context of an outbreak. Towards this scope, and in order to take advantage of the research opportunities afforded by any large-scale Ebola outbreak, CEPI is expected to facilitate the rapid launch of clinical studies of the lead Ebola vaccine candidates. If feasible, the standard CfP mechanism will be used. However, in duly justified emergencies CEPI may award a grant without a call for proposals.

RVF and EVD are included among the WHO R&D Blueprint list of priority pathogens in 2018, while CHIKV was deemed to present a major public health risks for which “further research and development is needed” and “efforts in the interim to understand and mitigate them are encouraged”. Despite this stated urgency, action has been lacking – in part because low and middle-income countries are most at risk for future outbreaks and market incentives are lacking, both due to this and the inherently unpredictable nature and timing of future outbreaks. The current pipeline of candidates for these three pathogens does however bring a lot of promise; since there are quite a few mature candidates in the pipeline, targeted investments from CEPI and the EC could bring significant benefit and further strengthen and align the two entities’ existing priorities in vaccine development.

 Deliverables

List of deliverables.
Opening of call online Documents, reports 2020-02-12 15:34:46
Project description template Documents, reports 2020-02-12 15:34:36

Take a look to the deliverables list in detail:  detailed list of ECRC deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ECRC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ECRC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

HEAP (2020)

Human Exposome Assessment Platform

Read More  

ECRC (2019)

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Read More  

EXIMIOUS (2020)

Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome

Read More